Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fusen Pharmaceutical Co., Ltd. has reported a significant downturn in its interim financial results for the first half of 2024, with revenues falling by 41.6% and gross profits down by 40.9% compared to the same period last year. The company also shifted from a profit of RMB 16.5 million in the first half of 2023 to a loss of RMB 36.9 million in the first half of 2024. This stark reversal highlights challenges faced by Fusen Pharmaceutical, potentially impacting investor confidence.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.